News & Highlights

February 2020

  • Lab moves to City of Hope National Medical Center
 
December 2019
  • Max Gordon wins Abstract Achievement Award at the 61stASH Annual Meeting in Atlanta for his presentation "The CLL Comorbidity Index (CLL-CI): a Novel Comorbidity Score"
 
September 2019
  • Scott Best wins a travel award to deliver an oral presentation at IWCLL2019 in Edinburgh, Scotland “Pevonedistat, a NAE inhibitor, is a favorable modulator of T cell function in ex vivo studies of CLL”

December 2018

  • Max Gordon wins Abstract Achievement Award at the 60th ASH Annual Meeting in Atlanta for his presentation "Impact of individual comorbidities on treatment outcomes in chronic lymphocytic leukemia"
 
September 2018
  • Scott Best wins Best Abstract Award for his oral presentation "TAK-243, a small molecule inhibitor of ubiquitin-activating enzyme (UAE), induces ER stress and apoptosis in CLL cells" at the NewYoung Investigator Meeting at the International Workshop on CLL in Cologne, Germany
 
July 2018
  • Alexey Danilov becomes a Leukemia and Lymphoma Society Scholar in Clinical Research
 
December 2017
  • Max Gordon wins Abstract Achievement Award at the 59th ASH Annual Meeting in Atlanta for his oral presentation "Medical comorbidities assessed by CIRS negatively impact survival in the era of targeted therapies in CLL: a multicenter retrospective analysis"
  • Scott Best wins Abstract Achievement Award at the 59th ASH Annual Meeting in Atlanta for his presentation "TAK-243, a small molecule inhibitor of ubiquitin-activating enzyme, induces ER stress and apoptosis in diffuse large B-cell lymphoma cells"
 
June 2017
  • Danilov lab awarded a Leukemia and Lymphoma Society Translational Research Program award
 
December 2016
  • Taylor Hashiguchi gives an oral presentation at the 58th ASH Annual Meeting in San Diego "Selective targeting cyclin-dependent kinase-9 (CDK9) downmodulates c-MYC and induces apoptosis in diffuse large B-cell lymphoma (DLBCL) cells"
  • Cody Paiva wins Abstract Achievement Award at the 58th ASH Annual Meeting in San Diego for his oral presentation "SYK inhibition disrupts the cross-talk between B-cell activation factor (BAFF) and B-cell receptor (BCR) and thereby antagonizes Mcl-1 in CLL B-cells"